Using CDK 4/6 inhibitors with radiation to improve treatment for advanced breast cancer
Project 3: Credentialing CDK 4/6 inhibitors used with radiation as an effective treatment strategy in locally advanced ER+ and TNBC
This study is looking at whether using CDK 4/6 inhibitors along with radiation therapy can help women with locally advanced estrogen receptor-positive or triple-negative breast cancer, especially those with more than three affected lymph nodes, by making the radiation treatment work better and reducing the chances of cancer coming back.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10917032 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of combining CDK 4/6 inhibitors with radiation therapy for women with locally advanced estrogen receptor-positive (ER+) and triple-negative breast cancer (TNBC). The study aims to address the high rates of locoregional recurrence in these patients, particularly those with more than three affected lymph nodes. By evaluating the potential of CDK 4/6 inhibitors as radiosensitizers, the research seeks to enhance the effectiveness of radiation therapy, which is a standard treatment for breast cancer. The approach involves clinical trials and assessments to determine the safety and efficacy of this combination treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with locally advanced ER+ or TNBC breast cancer, particularly those with more than three affected lymph nodes.
Not a fit: Patients with early-stage breast cancer or those who do not have ER+ or TNBC may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of cancer recurrence and improve survival rates for women with advanced breast cancer.
How similar studies have performed: While the use of CDK 4/6 inhibitors has shown promise in treating metastatic ER+ breast cancer, this specific combination with radiation therapy is relatively novel and has not been extensively tested.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Speers, Corey W. — University of Michigan at Ann Arbor
- Study coordinator: Speers, Corey W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.